LDLR and chronic kidney disease: Conversely, in the FinnGen database, LDLR agonists (OR [95% CI] = 1.394 [1.036, 1.875], p = 0.028) and PCSK9 inhibitors (OR [95% CI] = 1.404 [1.098, 1.795], p = 0.007) were significantly associated with an increased risk of CKD.